Protease-activated receptors in hemostasis, thrombosis and vascular biology

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 8, 2005, Pages 1800-1814

  Coughlin, Shaun R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN; TRYPTASE;

ANGIOGENESIS; CELL ACTIVITY; CONFERENCE PAPER; DISEASE MODEL; EMBRYO DEVELOPMENT; HEMOSTASIS; HUMAN; INFLAMMATION; KNOCKOUT MOUSE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; THROMBOSIS; TISSUE INJURY;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; CARDIOVASCULAR SYSTEM; ENDOTHELIUM, VASCULAR; HEMOSTASIS; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; PEPTIDE HYDROLASES; RECEPTORS, PROTEINASE-ACTIVATED; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 28344436780     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01377.x     Document Type: Conference Paper

References (187)

1. Colman RW, Marder VJ, Salzman EW, Hirsh J. Overview of Hemostasis. In: Colman RW, Marder VJ, Salzman EW, Hirsh J, eds. Hemostasis and Thrombosis. 3rd edn. Philadelphia: Lippincott, 1994: 3-18.
2. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-97.
3. Bevilacqua MP, Gimbrone MA Jr. Inducible endothelial functions in inflammation and coagulation. Semin Thromb Hemost 1987; 13: 425-33.
4. Camerer E, KolstØ AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 1-41.
5. Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998;9(Suppl. 1(6 Pt 2)): S9-14.
6. Giesen PL, Rauch U, Bohrmann B, Kling D, Roqué M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999; 96: 2311-5.
7. Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004; 104: 3190-7.
8. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, Wakefield TW, Mackman N, Fay WP. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005; 105: 192-8.
9. Coughlin SR. Sol Sherry lecture in thrombosis: how thrombin 'talks' to cells: molecular mechanisms and roles in vivo. Arterioscler Thromb Vasc Biol 1998; 18: 514-8.
10. Davey MG, Lüscher EF. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature 1967; 216: 857-8.
11. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 1975; 72: 2994-8.
12. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880-6.
13. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
14. Hughes PE, Pfaff M. Integrin affinity modulation. Trends Cell Biol 1998; 8: 359-64.
15. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. J Biol Chem 1989; 264: 17049-57.
16. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem 1989; 264: 7768-71.
17. Subramaniam M, Frenette PS, Saffaripour S, Johnson RC, Hynes RO, Wagner DD. Defects in hemostasis in P-selectin-deficient mice. Blood 1996; 87: 1238-2.
18. Frenette PS, Mayadas TN, Rayburn H, Hynes RO, Wagner DD. Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell 1996; 84: 563-74.
19. Lum H, Malik AB. Regulation of vascular endothelial barrier function. Am J Physiol 1994; 267 (3 Pt 1): L223-41.
20. Cirino G, Cicala C, Bucci MR, Sorrentino L, Maraganore JM, Stone SR. Thrombin functions as an inflammatory mediator through activation of its receptor. J Exp Med 1996; 183: 821-7.
21. Tesfamariam B, Allen GT, Normandin D, Antonaccio MJ. Involvement of the 'tethered ligand' receptor in thrombin-induced endothelium-mediated relaxations. Am J Physiol 1993;H 1744-9.
22. Hamilton JR, Frauman AG, Cocks TM. Increased expression of pro tease-activated receptor-2 (PA R2) and PA R4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ Res 2001; 89: 92-98.
23. Hamilton JR, Moffatt JD, Frauman AG, Cocks TM. Protease-activated receptor (PAR) 1 but not PAR2 or PAR4 mediates endothelium-dependent relaxation to thrombin and trypsin in human pulmonary arteries. J Cardiovasc Pharmacol 2001 ; V38 (N1): 108-19.
24. Ku DD, Zaleski JK. Receptor mechanism of thrombin-induced endothelium-dependent and endothelium-independent coronary vascular effects in dogs. J Cardiovasc Pharmacol 1993; 22: 609-16.
25. Chen EB, Teng NNH, Buchanan JM. Mitogenicity of thrombin and surface alterations on mouse splenocytes. Exp Cell Res 1976; 101: 41-46.
26. Chen EB, Buchanan JM. Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Natl Acad Sci USA 1975; 72: 131-5.
27. McNamara CA, Sarembok IJ, Gimple EW, Fenton JW II, Coughlin SR, Owens GK. Thrombin stimulation of smooth muscle cell proliferation is mediated by a proteolytic, receptor-mediated mechanism. J Clin Invest 1992; 91: 94-98.
28. Kranzhöfer R, Clinton SK, Ishii K, Coughlin SR, Fenton JW II, Eibby P. Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes. Circ Res 1996; 79: 286-94.
29. Naldini A, Carney DH, Bocci V, Klimpel KD, Asuncion M, Soares LE, Klimpel GR. Thrombin enhances T cell proliferative responses and cytokine production. Cell Immunol 1993; 147: 367-77.
30. Mari B, Imbert V, Belhacene N, Far DF, Peyron JF, Pouyssegur J, Van O, Schilling E, Rossi B, Auberger P. Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production. J Biol Chem 1994; 269: 8517-23.
31. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 1999; 96: 11023-7.
32. VuTK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
33. Rasmussen UB, Vouret-Craviari V, Jallat S, Schlesinger Y, Pagers G, Pavirani A, Lecocq JP, Pouyssegur J, Van Obberghen-Schilling E. cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett 1991; 288: 123-8.
34. Chen J, Ishii M, Wang L, Ishii K, Coughlin SR. Thrombin receptor activation: Confirmation of the intramolecular tethered liganding hypothesis and discovery of an alternative intermolecular liganding mode. J Biol Chem 1994; 269: 16041-5.
35. O'Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS, Brass LF. Thrombin Responses in Human Endothelial Cells. Contributions from receptors other than PARI include the transactivation of PAR2 by thrombin-cleaved PARI. J Biol Chem 2000; 275: 13502-9.
36. Vassallo RR Jr, Kieber-Emmons T, Cichowski K, Brass LF. Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J Biol Chem 1992; 267: 6081-5.
37. Scarborough RM, Naughton MA, Teng W, Hung DT, Rose J, Vu TK, Wheaton VI, Turck CW, Coughlin SR. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J Biol Chem 1992; 267: 13146-9.
38. Hollenberg MD. Proteinase-mediated signaling: proteinase-activated receptors (PARs) and much more. Life Sci 2003; 74: 237-46.
39. Vu T-KH, Wheaton VI, Hung DT, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature 1991; 353: 674-7.
40. Liu L, Vu T-KH, Esmon CT, Coughlin SR. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J Biol Chem 1991; 266: 16977-80.
41. Ishii K, Gerszten R, Zheng YW, Welsh JB, Turck CW, Coughlin SR. Determinants of thrombin receptor cleavage. Receptor domains involved, specificity, and role of the P3 aspartate. J Biol Chem 1995; 270: 16435-40.
42. Hung DT, Vu TK, Wheaton VI, Ishii K, Coughlin SR. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. J Clin Invest 1992; 89: 1350-3.
43. Mathews II, Padmanabhan KP, Ganesh V, Tulinsky A, Ishii M, Chen J, Turck CW, Coughlin SR, Fenton JW II. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry 1994; 33: 3266-79.
44. Hammes SR. Coughlin SR. Protease-activated receptor-1 can mediate responses to SFLLRN in thrombin-desensitized cells: evidence for a novel mechanism for preventing or terminating signaling by PARTs tethered ligand. Biochemistry 1999; 38: 2486-93.
45. Coller BS, Ward P, Ceruso M, Scudder LE, Springer K, Kutok J, Prestwich GD. Thrombin receptor activating peptides: importance of the N-terminal serine and its ionization state as judged by pH dependence, NMR spectroscopy, and cleavage by aminopeptidase M. Biochemistry 1992; 31: 11713-20.
46. Bode W, Schwager P, Huber R. The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. J Mol Biol 1978; 118:99-112.
47. Lerner DJ, Chen M, Tram T, Coughlin SR. Agonist recognition by proteinase-activated receptor 2 and thrombin receptor. Importance of extracellular loop interactions for receptor function. J Biol Chem 1996; 271: 13943-7.
48. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC. Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000; 289: 739-45.
49. Gerszten RE, Chen J, Ishii M, Ishii K, Wang L, Nanevicz T, Turck CW, Vu T-HK, Coughlin SR. The thrombin receptor's specificity for agonist peptide is defined by its extracellular surface. Nature 1994; 368: 648-51.
50. Nanevicz T, Ishii M, Wang L. Chen M, Chen J, Turck CW, Cohen FE. Coughlin SR. Mechanisms of thrombin receptor agonist specificity. Chimeric receptors and complementary mutations identify an agonist recognition site. J Biol Chem 1995; 270: 21619-25.
51. Nanevicz T, Wang L, Chen M, Ishii M, Coughlin SR. Thrombin receptor activating mutations. Alteration of an extracellular agonist recognition domain causes constitutive signaling. J Biol Chem 1996; 271: 702-6.
52. Bahou WF, Coller BS, Potter CL, Norton KJ, Kutok JL, Goligorsky MS. The thrombin receptor extracellular domain contains sites crucial for peptide-ligand induced activation. J Clin Invest 1993; 91: 1405-13.
53. Kim S, Foster C, Lecchi A, Quinton TM, Presser DM, Jin J, Cattaneo M, Kunapuli SP. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 2002; 99: 3629-36.
54. Seiler SM. Peluso M, Tuttle JG, Pryor K, Klimas C, Matsueda GR, Bernatowicz MS. Thrombin receptor activation by thrombin and receptor-derived peptides in platelet and CHRF-288 cell membranes: receptor-stimulated GTPase and evaluation of agonists and partial agonists. Mol Pharmacol 1996; 49: 190-7.
55. Barr AJ, Brass LF, Manning DR. Reconstitution of receptors and GTP-binding regulatory proteins (G proteins) in Sf9 cells. A direct evaluation of selectivity in receptor. G protein coupling. J Biol Chem 1997; 272: 2223-9.
56. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in G alpha(q)-deficient mice. Nature 1997; 389: 183-6.
57. Moers A, Nieswandt B, Massberg S, Wettschureck N, Gruner S, Konrad I, Schulte V. Aktas B. Gratacap MP, Simon MI, Gawaz M, Offermanns S. G(13) is an essential mediator of platelet activation in hemostasis and thrombosis. Nat Med 2003; 9: 1418-22.
58. Yang J, Wu J. Kowalska MA, Dalvi A, Prevost N, O'Brien PJ, Manning D, Poncz M, Lucki I. Blendy JA, Brass LF. Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci U S A 2000; 97: 9984-9.
59. Lefkowitz RJ, Pitcher J, Krueger K, Daaka Y. Mechanisms of beta-adrenergic receptor desensitization and resensitization. Adv Pharmacol 1998; 42: 416-20.
60. Hoxie JA, Ahuja M, Belmonte E, Pizarro S, Parton R, Brass LF. Internalization and recycling of activated thrombin receptors. J Biol Chem 1993; 268: 13756-63.
61. Ishii K, Chen J, Ishii M. Koch WJ, Freedman NJ, Lefkowitz RJ, Coughlin SR. Inhibition of thrombin receptor signaling by a G protein-coupled receptor kinase. Functional specificity among G protein-coupled receptor kinases. J Biol Chem 1994; 269: 1125-30.
62. Paing MM, Stutts AB, Kohout TA, Lefkowitz RJ, Trejo J. beta - Arrestins regulate pro tease-activated receptor-1 desensitization but not internalization or Down-regulation. J Biol Chem 2002; 277: 1292-300.
63. Hein L, Ishii K, Coughlin SR, Kobilka BK. Intracellular targeting and trafficking of thrombin receptors: a novel mechanism for resensitization of a G protein-coupled receptor. J Biol Chem 1994; 269: 27719-26.
64. Trejo J, Hammes SR, Coughlin SR. Termination of signaling by protease-activated receptor-1 is linked to lysosomal sorting. Proc Natl Acad Sci U S A 1998; 95: 13698-702.
65. Trejo J. Coughlin SR. The cytoplasmic tails of protease-activated receptor-1 and substance P receptor specify sorting to lysosomes versus recycling. J Biol Chem 1999; 274: 2216-24.
66. Ishii K, Hein L, Kobilka B, Coughlin SR. Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling. J Biol Chem 1993; 268: 9780-6.
67. Molino M, Blanchard N, Belmonte E, Tarver AP, Abrams C, Hoxie JA. Cerletti C, Brass LF. Proteolysis of the human platelet and endothelial cell thrombin receptor by neutrophil-derived cathepsin G. J Biol Chem 1995; 270: 11168-75.
68. Ludeman MJ. Zheng YW, Ishii K, Coughlin SR. Regulated shedding of PARI N-terminal exodomain from endothelial cells. J Biol Chem 2004: 279: 18592-9. Epub 2004 Feb 24.
69. Brass LF, Vassallo RJ, Belmonte E, Ahuja M, Cichowski K, Hoxie JA. Structure and function of the human platelet thrombin receptor. Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus. J Biol Chem 1992; 267: 13795-8.
70. Cook JJ, Sitko GR, Bednar B, Condra C, Mellott MJ, Feng DM, Nutt RF, Shafer JA, Gould RJ, Connolly TM. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 1995; 91: 2961-71.
71. Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ, Seiler SM. Development of potent thrombin receptor antagonist peptides. J Med Chem 1996; 39: 4879-87.
72. Andrade-Gordon P, Maryanoff BE, Derian CK, Zhang HC. Addo MF, Darrow AL, Eckardt AJ, Hoekstra WJ. McComsey DF, Oksenberg D, Reynolds EE, Santulli RJ, Scarborough RM, Smith CE, White KB. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci U S A 1999; 96: 12257-62.
73. Derian CK, Maryanoff BE, Zhang HC, Andrade-Gordon P. Therapeutic potential of protease-activated receptor-1 antagonists. Expert Opin Investig Drugs 2003; 12: 209-21.
74. Derian CK, Damiano BP, Addo MF, Darrow AL, D'Andrea MR, Nedelman M, Zhang HC. Maryanoff BE, Andrade-Gordon P. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003; 304: 855-61.
75. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667-72.
76. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Hebert JM. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-6.
77. Ishihara H. Connolly AJ, Zeng D, Kahn ML, Zheng YW. Timmons C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386: 502-6.
78. Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A 1998; 95: 6642-6.
79. Kahn ML, Zheng YW, Huang W, Bigorma V, Zeng D, Moff S, Farese RV Jr. Tarn C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690-4.
80. Riewald M, Petrovan RJ, Donner A, Ruf W. Activated protein C signals through the thrombin receptor PARI in endothelial cells. J Endotoxin Res 2003; 9: 317-21.
81. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci U S A 1994; 91: 9208-12.
82. Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A, Hoxie JA, Schechter N, Woolkalis M, Brass LF. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 1997; 272: 4043-9.
83. Camerer E, Røttingen JA, Iversen JG. Prydz H. Coagulation factors VII and X induce Ca2 + oscillations in Madin-Darby canine kidney cells only when proteolytically active. J Biol Chem 1996; 271: 29034-42.
84. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor Vila. Proc Natl Acad Sci U S A 2000; 97: 5255-60.
85. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci U S A 2001; 98: 7742-7.
86. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000; 404: 609-13.
87. Vu TK, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature 1991; 353: 674-7.
88. Liu LW, Vu TK, Esmon CT, Coughlin SR. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J Biol Chem 1991; 266: 16977-80.
89. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning of a potential proteinase activated receptor [see comments]. Proc Natl Acud Sci U S A 1994; 91: 9208-12.
90. Kahn ML, Nakanishi-Matsui M, Shapiro MJ. Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-87.
91. Faruqi TR, Weiss EJ, Shapiro MJ, Huang W, Coughlin SR. Struc-ture-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J Biol Chem 2000; 275: 19728-34.
92. Selak MA, Chignard M, Smith JB. Cathepsin G is a strong platelet agonist released by neutrophils. Biochem J 1988; 251: 293-9.
93. Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem 2000; 275: 6819-23.
94. Shapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J Biol Chem 2000; 275: 25216-21.
95. Covic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 2000; 39: 5458-67.
96. Offermanns S, Laugwitz KL, Spicher K, Schultz G. G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci U S A 1994; 91: 504-8.
97. Faruqi TR, Weiss EJ, Shapiro MJ, Hung W, Coughlin SR. Structure-function analysis of protease-activated receptor-4 tethered tigand peptides: Determinants of specificity and utility in assays of receptor function. J Biol Chem 2000; 275: 19728-34.
98. Okamura T, Hasitz M, Jamieson GA. Platelet glycocalicin: interaction with thrombin and role as thrombin receptor on the platelet surface. J Biol Chem 1978; 253: 3435-43.
99. Andrews RK, Shen Y, Gardiner EE, Dong JF, Lopez JA, Berndt MC. The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. Thromh Haemosl 1999; 82: 357-64.
100. Ware J, Russell SR, Vicente V, Scharf RE, Tomer A, McMillan R, Ruggeri ZM. Nonsense mutation in the glycoprotein Ib alpha coding sequence associated with Bernard-Soulier syndrome. Proc Natl Acad Sci U S A 1990; 87: 2026-30.
101. De Marco L, Mazzucato M, Fabris F, De Roia D, Coser P, Girolami A, Vicente V, Ruggeri ZM. Variant Bernard-Soulier syndrome type bolzano. A congenital bleeding disorder due to a structural and functional abnormality of the platelet glycoprotein Ib-IX complex. J Clin Invest 1990; 86: 25-31.
102. De Marco L, Mazzucato M, Masotti A, Fenton JWd, Ruggeri ZM. Function of glycoprotein Ib alpha in platelet activation induced by alpha-thrombin. J Biol Chem 1991; 266: 23776-83.
103. Ruggeri ZM. The platelet glycoprotein Ib-IX complex. Prog Hemost Thromb 1991; 10: 35-68.
104. De Marco L, Mazzucato M, Masotti A, Ruggeri ZM. Localization and characterization of an alpha-thrombin-binding site on platelet glycoprotein Ib alpha. J Biol Chem 1994; 269: 6478-84.
105. De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem 2001; 276: 4692-8. Epub 2000 Nov 17.
106. Celikel R, McClintock RA, Roberts JR, Mendolicchio GL, Ware J, Varughese KI, Ruggeri ZM. Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha. Science 2003; 301: 218-21.
107. Connolly AJ, Ishihara H, Kahn ML, Farese RV Jr, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996; 381: 516-9.
108. Connolly TM, Condra C, Feng DM, Cook JJ, Stranieri MT, Reilly CF, Nutt RF, Gould RJ. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemost 1994; 72: 627-33.
109. Derian CK, Santulli RJ, Tomko KA, Haertlein BJ, Andrade-Gordon P. Species differences in platelet responses to thrombin and SFLLRN. Receptor-mediated calcium mobilization and aggregation and regulation by protein kinases. Thromb Res 1995; 6: 505-19.
110. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. [Comment In: Nature. 2001 Sep 6;413(6851):26-7 UI: 21429411]. Nature 2001; 413: 74-8.
111. Ramakrishnan V. Reeves PS, DeGuzman F, Deshpande U, Ministri-Madrid K, DuBridge RB, Phillips DR. Increased thrombin responsiveness in platelets from mice lacking glycoprotein V. PWL- Natl Acad Sci U S A 1999; V96 (N23): 13336-41.
112. Ramakrishnan V. DeGuzman F, Bao M, Hall SW. Leung LL. Phillips DR. A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. Proc Natl Acad Sci U S A 2001; 98: 1823-8.
113. Hamilton JR, Cornelissen I, Coughlin SR. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost 2004; 2: 1429-35.
114. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102: 449-61. Epub 2003 Mar 20.
115. Kunapuli SP, Dorsam RT. Kim S, Quinton TM. Platelet purinergic receptors. Curr Opin Pharmacol 2003; 3: 175-80.
116. Suh TT, Holmback K, Jensen NJ, Daugherty CC, Small K, Simon DI, Potter S, Degen JL. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9: 2020-33.
117. Sun WY, Witte DP. Degen JL, Colbert MC, Burkart MC, Holmbäck K, Xiao Q, Bugge TH, Degen SJ. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A 1998; 95: 7597-602.
118. Xue J, Wu Q, Westfield LA, Tuley EA. Lu D, Zhang Q, Shim K, Zheng X, Sadler JE. Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice. Proc Natl Acad Sci U S A 1998; 95: 7603-7.
119. Camerer E, Duong DN. Hamilton JR, Coughlin SR. Combined deficiency of protease-activated receptor-4 and fibrinogen recapitulates the hemostatic defect but not the embryonic lethality of prothrombin deficiency. Blood 2004; 103: 1524.
120. Carmeliet P, Mackman N, Moons L, Luther T. Gressens P, Van VI, Demunck H, Kasper M, Breier G, Evrard P. Muller M, Risau W. Edgington T, Collen D. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383: 73-5.
121. Griffin CT, Snnivasan Y, Zheng YW, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. [Comment In: Science. 2001 Aug 31:293(5535): 1602 4 UI: 21425318]. Science 2001; 293: 1666-70.
122. Weiss EJ, Hamilton JR, Lease KE, Coughlin SR. Protection against thrombosis in mice lacking PA R3. Blood 2002; 100: 3240-4.
123. Vandendries ER, Hamilton JA, Coughlin SR, Furie BC. Furie B. Protease-activated receptor 4 is required for maximal thrombus growth but not for fibrin generation in thrombi after laser injury. Blood 2004; 104: 181a.
124. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, Jackson CW, Hunt P, Saris CJ, Orkin SH. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin MGDF in megakaryocyte development. Cell 1995; 81: 695-704.
125. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165-74.
126. Tracy PB. Regulation of thrombin generation at cell surfaces. Semin Thromb Hemost 1988; 14: 227-33.
127. Reverter JC. Beguin S. Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'. J Clin Invest 1996; 98: 863-74.
128. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-45.
129. Zimmerman GA, Elstad MR, Lorant DE, McLntyre TM, Prescott SM, Topham MK. Weyrich AS, Whatley RE. Platelet-activating factor (PAF): signalling and adhesion in cell-cell interactions. Adv Exp Med Biol 1996; 416: 297-304.
130. Johnson K, Choi Y, DeGroot E. Samuels I, Creasey A, Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998; 160: 5130-5.
131. Houliston RA, Keogh RJ, Sugden D, Dudhia J, Carter TD, Wheeler-Jones CP. Protease-activated receptors upregulate cyclooxygenase-2 expression in human endothelial cells. Thromb Haemost 2002; 88: 321-8.
132. Weksler BB, Ley CW, Jaffe EA. Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187. J Clin Invest 1978; 62: 923-30.
133. Kataoka H. Hamilton JR. McKemy DD, Camerer E, Zheng YW, Cheng A. Griffin C, Coughlin SR. Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood 2003; 102: 3224-31.
134. Camerer E. Kataoka H. Kahn M, Lease K, Coughlin SR. Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. J Biol Chem 2002; 277: 16081-7.
135. Trejo J. Connolly AJ, Coughlin SR. The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice. J Biol Chem 1996; 271: 21536-41.
136. McNamara CA. Sarembock IJ, Gimple LW, Fenton JW Jr, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993:91:94-8.
137. Loppnow H, Bil R. Hirt S, Schonbeck U, Herzberg M, Werdan K, Rietschel ET, Brandt E, Flad HD. Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. Blood 1998; 91: 134-41.
138. SteinhoffM. Vergnolle N. Young SH, Tognetto M, Amadesi S, Ennes HS, Trevisani M, Hollenberg MD, Wallace JL, Caughey GH, Mitchell SE. Williams LM. Geppetti P. Mayer EA, Bunnett NW. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000; 6: 151-8.
139. de Garavilla L. Vergnolle N, Young SH, Ennes H, Steinhoff M, Ossovskaya VS. D'Andrea MR, Mayer EA, Wallace JL, Hollenberg MD. Andrade-Gordon P, Bunnett NW. Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. Br J Pharmacol 2001; 133: 975-87.
140. Vergnolle N, Bunnett NW, Sharkey KA, Brussee V, Compton SJ, Grady EF, Cirino G. Gerard N, Basbaum AI, Andrade-Gordon P, Hollenberg MD. Wallace JL. Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat Med 2001; 7: 821-6.
141. Coughlin SR, Camerer E. PARticipation in inflammation. J Clin Invest 2003; 111: 25-27.
142. Cunningham MA, Rondeau E. Chen X, Coughlin SR, Holdsworth SR. Tipping PG. Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med 2000; 191: 455-62.
143. Cheung WM. D'Andrea MR, Andrade-Gordon P, Damiano BP. Altered vascular injury responses in mice deficient in protease-activated receptor-1. Arlerioscler Thromb Vase Biol 1999; 19: 3014-24.
144. Andrade-Gordon P, Derian CK, Maryanoff BE, Zhang HC, Addo MF. Cheung W, Damiano BP, D'Andrea MR, Darrow AL, de Garavilla L, Eckardt AJ, Giardino EC, Haertlein BJ, McComsey DF. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther 2001; 298: 34-42.
145. Takada M, Tanaka H, Yamada T, Ito O, Kogushi M, Yanagimachi M, Kawamura T, Musha T, Yoshida F, Ito M, Kobayashi H, Yoshitake S, Saito I. Antibody to thrombin receptor inhibits neoin-timal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. Circ Res 1998; 82: 980-7.
146. Vergnolle N. Cellars L, Mencarelli A, Rizzo G, Swaminathan S, Beck P, Steinhoff M, Andrade-Gordon P, Bunnett NW, Hollenberg MD, Wallace JL, Cirino G. Fiorucci S. A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest 2004; 114: 1444-56.
147. Lindner JR, Kahn ML, Coughlin SR, Sambrano GR, Schauble E, Bernstein D, Foy D, Hafezi-Moghadam A, Ley K. Delayed onset of inflammation in protease-activated receptor-2- deficient mice. J Immunol 2000; 165: 6504-10.
148. Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE, Smith AJH, Hunter GD, McLean JS, McGarry F, Ramage R, Jiang L, Kanke T, Kawagoe J. Essential role for proteinase activated receptor-2 in arthritis. J Clin Invest 2003: 111: 35-41.
149. Kawagoe J, Takizawa T, Matsumoto J. Tamiya M. Meek SE. Smith AJ, Hunter GD. Plevin R, Saito N, Kanke T, Fujii M, Wada Y. Effect of protease-activated receptor-2 deficiency on allergic dermatitis in the mouse ear. Jpn J Pharmacol 2002; 88: 77-84.
150. Seeliger S, Derian CK, Vergnolle N, Bunnett NW. Nawroth R, Schmelz M. Von Der Weid PY, Buddenkotte J. Sunderkotter C, Metze D, Andrade-Gordon P, Harms E, Vestweber D. Luger TA, Steinhoff M. Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo. FASEB J 2003; 17: 1871-85.
151. Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, Boisvert W, Andrade-Gordon P, Frank RD, Mackman N. Role of tissue factor and protease activated receptors in a mouse model of endotoxemia. Blood 2003; 23: 23.
152. Pawlinski R, Mackman N. Tissue factor, coagulation proteases. and protease-activated receptors in endotoxemia and sepsis. Crit Care Med 2004; 32 (Suppl. 5): S293-7.
153. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-2.
154. Cheng T, Liu D, Griffin JH, Fernandez JA. Castellino F, Rosen ED, Fukudome K, Zlokovic BV. Activated protein C blocks p53-mediated apoptosis in ischemie human brain endothelium and is neuroprotective. Nat Med 2003; 3: 3.
155. Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernandez JA, Griffin JH, Zlokovic BV. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 2004; 41: 563-72.
156. Junge CE, Sugawara T, Mannaioni G, Alagarsamy S, Conn PJ, Brat DJ, Chan PH, Traynelis SF. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Nail Acad Sci U S A 2003; 100: 13019-24.
157. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-64.
158. Domotor E, Benzakour O, Griffin JH, Yule D, Fukudome K, Zlokovic BV. Activated Protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of Protease Activated Receptor-1. Blood 2003; 13: 13.
159. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003; 373 (Pt 1): 65-70.
160. Ludeman MJ, Kataoka H, Srinivasan Y, Esmon N, Esmon CT, Coughlin SR. PARI cleavage and signaling in response to activated protein C and thrombin. (Submitted) 2005.
161. Flynn AN, Buret AG. Proteinase-activated receptor 1 (PAR-1) and cell apoptosis. Apoptosis 2004; 9: 729-737.
162. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105: 3178-84.
163. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger TA, Hollenberg MD. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 2005; 26: 1-43.
164. Bugge TH, Xiao Q, Kombrinck KW, Flick MJ, Holmbäck K, Danton MJ, Colbert MC, Witte DP, Fujikawa K, Davie EW, Degen JL. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci U S A 1996; 93: 6258-63.
165. Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 1996; 384: 66-8.
166. Offermanns S, Mancino V, Revel JP, Simon MI. Vascular system defects and impaired cell chemokinesis as a result of Galpha13 deficiency. Science 1997; 275: 533-6.
167. Hung DT, Wong YH, Vu T-KH, Coughlin SR. The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate both phosphoinositide hydrolysis and inhibit adenylyl cyclase. J Biol Chem 1992:353:20831-4.
168. Offermanns S, Laugwitz K-L, Spicher K, Schultz G. G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci U S A 1994; 91: 504-508.
169. Kozasa T, Jiang X, Hart MJ, Sternweis PM, Singer WD, Oilman AG, Bollag G, Sternweis PC. pi 15 RhoGEF, a GTPase activating protein for Galphal2 and Galphal3. Science 1998; 280: 2109-11 [see comments].
170. Hart MJ, Jiang X, Kozasa T, Roscoe W, Singer WD, Gilman AG, Sternweis PC, Bollag G. Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by Galphal3. Science 1998; 280: 2112-4 [see comments].
171. Fukuhara S, Murga C, Zohar M, Igishi T, Gutkind JS. A novel PDZ domain containing guanine nucleotide exchange factor links heterotrimeric G proteins to Rho. J Biol Chem 1999; 274: 5868-79.
172. Klages B, Brandt U, Simon MI, Schultz G, Offermanns S. Activation of G 12/G13 results in shape change and rho/rho kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999; 144: 745-54.
173. Vouret-Craviari V, Boquet P, Pouyssegur J, Van Obberghen-Schilling E. Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function. Mol Biol Cell 1998; 9: 2639-53.
174. Taylor S, Chae H, Rhee S-G, Exton J. Activation of the B1 isozyme of phospholipase C by a subunits of the Gq class of G proteins. Nature 1991; 350: 516-8.
175. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, Malek D, Stoyanova S, Vanhaesebroeck B, Dhand R, Nürnberg B. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 1995; 269: 690-3.
176. Clapham DE, Neer EJ. G protein beta gamma subunits. Annu Rev Pharmacol Toxicol 1997; 37: 167-203.
177. Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 1999; 11: 219-25.
178. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402: 884-8.
179. Ali H, Tomhave ED, Richardson RM, Haribabu B, Snyderman R. Thrombin primes responsiveness of selective chemoattractant receptors at a site distal to G protein activation. J Biol Chem 1996; 271: 3200-6.
180. Colotta F, Sciacca FL, Sironi M, Luini W, Rabiet MJ, Mantovani A. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 1994; 144: 975-85.
181. Ueno A, Murakami K, Yamanouchi K, Watanabe M, Kondo T. Thrombin stimulates production of interleukin-8 in human umbilical vein endothelial cells. Immunology 1996; 88: 76-81.
182. Garcia JG, Siflinger-Birnboim A, Bizios R, Del Vecchio PJ, Fenton JWd, Malik AB. Thrombin-induced increase in albumin permeability across the endothelium. J Cell Physiol 1986; 128: 96-104.
183. Eum H, Andersen TT, Siflinger-Birnboim A, Tiruppathi C, Goligorsky MS, Fenton JWd, Malik AB. Thrombin receptor peptide inhibits thrombin-induced increase in endothelial permeability by receptor desensidzation. J Cell Biol 1993; 120: 1491-9.
184. Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C. Hsu YM, Sajer SA, Furie B. Eeukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-51.
185. Nystedt S, Ramakrishnan V, Sundelin J. The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor. J Biol Chem 1996; 271: 14910-5.
186. Esmon CT. Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood 2000; 95: 1113-1116.
187. Inbal A, Kenet G, Zivelin A, Yermiyahu T, Bronstein T, Sheinfeld T, Tamari H, Gitel S, Eshel G. Duchemin J, Aiach M, Seligsohn U. Purpura fulminans induced by disseminated intravascular coagulation following infection in 2 unrelated children with double heterozygosity for factor V Leiden and protein S deficiency. Thromb Haemost 1997; 77: 1086-9.